Treatment for C difficile Shows Promising Potential in First-in-Human Phase 1 Trial
October 6th 2019A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
Read More